ArticleEndocrine pathology2019
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Article in Endocrine pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.World neurosurgery · 2021Pooled it
- Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature.Journal of endocrinological investigation · 2020Pooled it
- Article
- Impact of granulation pattern on surgical and long-term outcomes in Cushing's disease: a comparative study of DGCT and SGCT.Pituitary · 2026Article
- Differential expression of cyclin D1 in pituitary neuroendocrine tumours: Relation to aggressive potential.African journal of laboratory medicine · 2026Article
- Histogram analysis based on contrast-enhanced T1-weighted imaging in pituitary macroadenomas: relation to histological subtype and expression.Quantitative imaging in medicine and surgery · 2026Article
- Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study.Journal of endocrinological investigation · 2025Article
- The Roles of PD-L1, Ki-67, P53, and Cyclin D1 in PitNETs: Diagnostic and Prognostic Implications in a Series of 74 Patients.International journal of molecular sciences · 2025Article
- Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading.Neuroradiology · 2025Article
- Molecular signatures of invasive and non-invasive pituitary adenomas: a comprehensive analysis of DNA methylation and gene expression.BMC medicine · 2025Article
- Article
- Endoscope-assisted transcranial surgery for complex pituitary adenoma: a retrospective case series study with propensity score matching.Neurosurgical review · 2025Article
- Long-term tumor control following repeat gamma-knife radiosurgery of growing pituitary adenomas: a population-based cohort study.Acta neurochirurgica · 2024Article
- Article
- Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.Immunity, inflammation and disease · 2024Review
- Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study.Biomedicines · 2023Article
- MRI and Trouillas' grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values.Neuroradiology · 2023Article
- Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.European radiology · 2023Article
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Non-functioning pituitary macroadenoma following surgery: long-term outcomes and development of an optimal follow-up strategy.Frontiers in surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fourth edition of the World Health Organization (WHO) classification of pituitary tumors recommended evaluation of tumor proliferation and invasion to identify aggressiveness. We aimed to assess the prognostic roles of the Ki-67 proliferation index, mitotic index, P53 expression, and cavernous sinus invasion in pituitary adenomas (PAs). Among the 601 patients who underwent transnasal/transsphenoidal adenomectomy from 2001 to 2016, 101 patients (16.8%) who had tumors with a high (≥ 3%) Ki-67 index (group A) and a control group consisting of 43 patients with a low (< 3%) Ki 67 index who were matched for age, gender, and tumor type were included. Mitotic index and P53 expressions were evaluated. Patient characteristics, histopathology reports, pre/postoperative magnetic resonance imaging (MRI), and follow-up data were assessed retrospectively. The frequency of macroadenomas and mean tumor size were greater in group A when compared to group B (67.4 vs. 94.1%, p< 0.01 and 25 ± 10.6 vs. 18 ± 11 mm, p< 0.01, respectively). Invasion to cavernous sinus was found in 53 (36.8%) patients and was more frequent in group A (p<0.01). The mean number of surgery was higher in group A than group B (p< 0.05). The mean follow-up period was 46.6 ± 34 months. The postoperative MRIs and follow-up data for at least 24 months were available in 117 patients. Recurrence risk was higher in group A than group B (p = 0.03). Tumors with high Ki-67 proliferation index were grouped as 3-5, 6-10, 11-15, and > 15%. The risk of recurrence was not different between groups of high Ki-67 index. The optimal cutoff point of the Ki-67 proliferation index that predicted recurrence was 2.5% with 84.6% sensitivity and 47.4% specificity. The cavernous sinus invasion on MRI was associated with recurrence (p = 0.03). Tumor size and recurrence risk were not associated with P53 expression. High P53 expression was related with cavernous sinus invasion (p = 0.03). The mitotic index was not associated with recurrence risk and tumor invasion. Recurrence risk was higher in tumors with ≥ 2 histopathological atypia criteria (p = 0.01). High Ki-67 index with a 2.5% cutoff point and cavernous sinus invasion on MRI are reliable markers for predicting recurrence in PAs. Recurrence risk is also higher in tumors with two histopathological aggressiveness criteria. Strict follow-up and more aggressive treatment approaches may be necessary for invasive-proliferative PAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.